Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nicholas Fidelman, MD
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of metastatic colorectal, neuroendocrine, cholangiocarcinoma, melanoma, or breast malignancy with liver dominant disease. Diagnosis may be made by histo- or cyto-pathology, or by clinical and imaging criteria.
The cancer is unresectable.
All patients must be off all chemotherapeutic regimens for 30 days prior to and 30 days after TheraSphere treatment. Concurrent therapy with octreotide is permitted, when appropriate.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Age 18 years or older.
Able to understand informed consent.
You may not be if
Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs on either:
* single TheraSphere administration; or
* cumulative delivery of radiation to the lungs greater than 50 Gy over multiple treatments.
Evidence of any detectable Tc-99m macroaggregated albumin deposition in the stomach or duodenum, after application of established angiographic techniques to stop such deposition.
Previous radiation therapy to the lungs and/or to the upper abdomen
Pregnancy
Symptomatic lung disease.
Significant extrahepatic disease representing an imminent life-threatening outcome.
Active uncontrolled infection
Any pre-treatment laboratory findings within 30 days of treatment demonstrating:
* Aspartate or alanine aminotransferase level greater than 5 times upper normal limit.
* Serum bilirubin greater than 2 mg/dl
* Infiltrative tumor on imaging
* Tumor volume greater than 70% of liver volume
* Tumor volume greater than 50% of liver volume and serum albumin level less than 3 mg/dL
Clareo Health | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
